| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2123822 | European Journal of Cancer | 2010 | 5 Pages |
Abstract
In this randomised phase II trial the addition of pravastatin to ECC did not improve outcome in patients with advanced gastric cancer. Therefore, further testing of this combination in a randomised phase III trial cannot be recommended.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Inge R.H.M. Konings, A. van der Gaast, Lidemarie J. van der Wijk, Felix E. de Jongh, Ferry A.L.M. Eskens, Stefan Sleijfer,